Because of the encouraging results of the KEYNOTE‐158 trial, the U.S. Food and Drug Administration (FDA) approved the use of pembrolizumab in metastatic/recurrent PD‐L1 positive cervical cancer after first‐line therapy in 2018. This evidence concerns the gene CD274 and cervical cancer.